|
|
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4503-4506.
Prepublished online as a Blood First Edition Paper on September 23, 2008; DOI 10.1182/blood-2008-05-157859.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS AND STEM CELLS
Brief Report
Trisomy 21 enhances human fetal erythro-megakaryocytic development
Stella T. Chou1,2,
Joanna B. Opalinska1,
Yu Yao1,
Myriam A. Fernandes1,
Anna Kalota3,
John S. J. Brooks4,
John K. Choi5,
Alan M. Gewirtz3,
Gwenn-ael Danet-Desnoyers3,
Richard L. Nemiroff6, and
Mitchell J. Weiss1,2
1 Division of Hematology, The Children's Hospital of Philadelphia, PA;
2 Department of Pediatrics, and
3 Division of Hematology/Oncology, The University of Pennsylvania School of Medicine, Philadelphia;
4 Department of Pathology, Pennsylvania Hospital, Philadelphia;
5 Department of Pathology, The Children's Hospital of Philadelphia, PA; and
6 Department of Obstetrics and Gynecology, The University of Pennsylvania School of Medicine, Philadelphia
Children with Down syndrome exhibit 2 related hematopoietic diseases: transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL). Both exhibit clonal expansion of blasts with biphenotypic erythroid and megakaryocytic features and contain somatic GATA1 mutations. While altered GATA1 inhibits erythro-megakaryocytic development, less is known about how trisomy 21 impacts blood formation, particularly in the human fetus where TMD and AMKL originate. We used in vitro and mouse transplantation assays to study hematopoiesis in trisomy 21 fetal livers with normal GATA1 alleles. Remarkably, trisomy 21 progenitors exhibited enhanced production of erythroid and megakaryocytic cells that proliferated excessively. Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors. This may predispose to TMD and AMKL by increasing the pool of cells susceptible to malignant transformation through acquired mutations in GATA1 and other cooperating genes.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Trisomy 21 tilts the balance
- Shai Izraeli
Blood 2008 112: 4361-4362.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. P. Lambert, Y. Wang, K. H. Bdeir, Y. Nguyen, M. A. Kowalska, and M. Poncz
Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes
Blood,
September 10, 2009;
114(11):
2290 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Xavier, Y. Ge, and J. W. Taub
Down Syndrome and Malignancies: A Unique Clinical Relationship: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2009;
11(5):
371 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Salek-Ardakani, G. Smooha, J. de Boer, N. J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H. J.M. Brady
ERG Is a Megakaryocytic Oncogene
Cancer Res.,
June 1, 2009;
69(11):
4665 - 4673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. K. Wiseman, K. A. Alford, V. L.J. Tybulewicz, and E. M.C. Fisher
Down syndrome--recent progress and future prospects
Hum. Mol. Genet.,
April 15, 2009;
18(R1):
R75 - R83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet.,
April 15, 2009;
18(R1):
R84 - R93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood,
March 19, 2009;
113(12):
2619 - 2628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
